David S. Russell, MD, PhD
Director, Clinical Research, Institute for Neurodegenerative DisordersDownloadHi-Res Photo
About
Titles
Director, Clinical Research, Institute for Neurodegenerative Disorders; Assistant Clinical Professor
Positions outside Yale
Senior Director, Clinical Research, Translational Research, Invicro
Biography
Dr. Russell is a neurologist specializing in movement disorders, dementias, and other neurodegenerative disorders. He is working full-time within a clinical research institute, devoted entirely to clinical research on diseases with major unmet needs. As a former director of the Yale Movement Disorders Consultation Clinic, he continues to work closely with other area neurologists and researchers to try to help improve the future for people with these diseases. Referrals to the Institute for Negenerative Disorders for potential research participation can be made most efficiently through the patient's treating neurologist or other physician.
Appointments
Psychiatry
Assistant Clinical ProfessorPrimaryNeurology
Assistant Clinical ProfessorSecondary
Other Departments & Organizations
Education & Training
- Neurology Resident
- Yale-New Haven Hospital (1995)
- Chief Resident, Neurology
- Yale-New Haven Hospital (1995)
- Intern
- Yale-New Haven Hospital (1992)
- MD
- Cornell University (1991)
- PhD
- Cornell University (1991)
- BA
- Oberlin College, Biology (1982)
Research
Overview
Medical Subject Headings (MeSH)
Alzheimer Disease; Huntington Disease; Movement Disorders; Neurodegenerative Diseases; Parkinson Disease
Research at a Glance
Yale Co-Authors
Frequent collaborators of David S. Russell's published research.
Publications Timeline
A big-picture view of David S. Russell's research output by year.
Research Interests
Research topics David S. Russell is interested in exploring.
Gilles Tamagnan, PhD
Catharine Duman, PhD
Stephen Strittmatter, MD, PhD, AB
39Publications
2,382Citations
Parkinson Disease
Publications
2024
Glutamatergic Dysfunction in Autism Spectrum Disorder (P1-8.001)
Brasic J, Nandi A, Russell D, Jennings D, Barret O, Slifer K, Sedlak T, Seibyl J, Berry-Kravis E, Wong D, Budimirovic D. Glutamatergic Dysfunction in Autism Spectrum Disorder (P1-8.001). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204347.Peer-Reviewed Original Research
2023
Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration
Koga S, Metrick M, Golbe L, Santambrogio A, Kim M, Soto-Beasley A, Walton R, Baker M, De Castro C, DeTure M, Russell D, Navia B, Sandiego C, Ross O, Vendruscolo M, Caughey B, Dickson D. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathologica Communications 2023, 11: 88. PMID: 37264457, PMCID: PMC10236843, DOI: 10.1186/s40478-023-01584-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSuperior frontal gyrusFrontal gyrusConsistent with corticobasal degenerationConsistent with progressive supranuclear palsyMotor cortexCorticobasal degenerationProgressive supranuclear palsyPosterior cortical areasPresentation of corticobasal degenerationSubtype of frontotemporal lobar degenerationRichardson's syndromeBrain regionsOccipital cortexSubcortical structuresCaudate nucleusFrontotemporal lobar degenerationTau PET scansSubstantia nigraGlobus pallidusCorticobasal syndromeGyrusSupranuclear palsyCortexCortical areasClinical presentation of progressive supranuclear palsy
2022
In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease
Bohorquez S, Constantinescu C, Manser P, Gunn R, Russell D, Tonietto M, Bullich S, Stephens A, Mueller A, Klein G, Teng E, Pickthorn K. In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063517.Peer-Reviewed Original ResearchConceptsChoroid plexusAlzheimer's diseaseTau pathology distributionModerate AD subjectsTarget cortical regionsTherapeutic trialsTau pathologyHead studiesPathology distributionCentrum semiovaleCortical greyBraak regionsAD subjectsHuman studiesInferior cerebellumSubcortical regionsHead comparisonQuantification scaleCortical regionsSubcortical structuresMinute imagesCSF spaceDiseaseUnimpaired subjectsSUVRPROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH
Tempest P, Lin Y, Tai C, Ono M, Russell D, Sandiego C, Carroll V, Gunn R, Margolin R, Higuchi M, Jang M. PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063028.Peer-Reviewed Original ResearchConceptsAD subjectsMulticenter phase 2 clinical trialAlzheimer's diseasePhase 2 clinical trialTau PET tracersPET imaging agentSimilar brain regionsCortical uptakeTest-retest studyCN subjectsClinical trialsNormal subjectsTau tracersBrain regionsSUV valuesDiverse tauopathiesPET tracersSame rank orderSUVR imagesImaging agentImaging profileDiseaseIn Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease
Bohorquez S, Constantinescu C, Manser P, Gunn R, Russell D, Tonietto M, Bullich S, Stephens A, Mueller A, Klein G, Teng E, Pickthorn K. In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063513.Peer-Reviewed Original ResearchConceptsChoroid plexusAlzheimer's diseaseTau pathology distributionModerate AD subjectsTarget cortical regionsTherapeutic trialsTau pathologyHead studiesPathology distributionCentrum semiovaleCortical greyBraak regionsAD subjectsHuman studiesInferior cerebellumSubcortical regionsHead comparisonQuantification scaleCortical regionsSubcortical structuresMinute imagesCSF spaceDiseaseUnimpaired subjectsSUVRPROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH
Tempest P, Lin Y, Tai C, Ono M, Russell D, Sandiego C, Gunn R, Carroll V, Margolin R, Kao T, Higuchi M, Jang M. PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063025.Peer-Reviewed Original ResearchConceptsAD subjectsMulticenter phase 2 clinical trialAlzheimer's diseasePhase 2 clinical trialTau PET tracersPET imaging agentSimilar brain regionsCortical uptakeTest-retest studyCN subjectsClinical trialsNormal subjectsTau tracersBrain regionsSUV valuesDiverse tauopathiesPET tracersSame rank orderSUVR imagesImaging agentImaging profileDisease
2021
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers
Kielbasa W, Shcherbinin S, Goldsmith P, Phipps K, Biglan K, Mancini M, Russell D, Constantinescu C, Gunn R, Nuthall H, Mergott D, Lowe S, Collins E. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.057774.Peer-Reviewed Original ResearchCitationsConceptsHealthy volunteersEnzyme occupancyPET scansSingle doseMultiple-dose clinical studiesPost-dose intervalPositron emission tomography radioligandBaseline PET scanLonger clinical trialsTarget occupancyTau-related diseasesMultiple dosesMultiple dosingClinical trialsPlasma pharmacokineticsClinical studiesEfficacy trialsSD studiesDose selectionTomography radioligandEnzyme inhibitorsPotential treatmentAlzheimer's diseasePET studiesTarget engagementMEASUREMENT OF CEREBRAL EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 IN AUTISM SPECTRUM DISORDER AND FRAGILE X SYNDROME
Brasic J, Budimirovic D, Nandi A, Russell D, Jennings D, Barret O, Martin S, Sllifer K, Berry-Kravis E, Wong D. MEASUREMENT OF CEREBRAL EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 IN AUTISM SPECTRUM DISORDER AND FRAGILE X SYNDROME. Journal Of The American Academy Of Child & Adolescent Psychiatry 2021, 60: s257. DOI: 10.1016/j.jaac.2021.09.413.Peer-Reviewed Original ResearchCitationsReduced Metabotropic Glutamate Receptor Subtype 5 in Fragile X Syndrome (4378)
Brasic J, Nandi A, Russell D, Jennings D, Barret O, Mathur A, Slifer K, Sedlak T, Martin S, Brinson Z, Vyas P, Seibyl J, Berry-Kravis E, Wong D, Budimirovic D. Reduced Metabotropic Glutamate Receptor Subtype 5 in Fragile X Syndrome (4378). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.4378.Peer-Reviewed Original ResearchCitations
2020
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human
Shcherbinin S, Kielbasa W, Dubois S, Lowe S, Phipps K, Tseng J, Kevin D, Natanegara F, Warner S, Dreyfus N, Lindsay‐Scott P, Hawk M, McDonald N, Zhang X, Gilmore J, Biglan K, Mergott D, Russell D, Gunn R, Constantinescu C, Nuthall H, Collins E. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.040558.Peer-Reviewed Original ResearchCitationsConceptsPET scansEnzyme occupancyHealthy volunteersPlasma concentration-dependent increaseSingle oral dose studyOral dose studyBaseline PET scanSingle oral doseTau-related diseasesDose-dependent changesConcentration-dependent increaseHuman PET studiesDose cohortsOral doseSingle dosesDose studyClinical studiesEfficacy trialsPharmacokinetic samplesFrontal cortexInitial cohortDose selectionHigh doseNumber of subjectsEnzyme inhibitors
News & Links
Get In Touch
Contacts
Appointment Number
Office Fax Number
Mailing Address
Psychiatry
Temple Medical Center, 60 Temple St., Suite 8B
New Haven, CT 06510
United States